Abigail Allen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Abigail Allen has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Partha Roy
University of Pittsburgh
5 shared publications - David Gau
University of Pittsburgh
4 shared publications - David N. Boone
University of Pittsburgh Department of Biomedical Informatics, Pittsburgh, USA
2 shared publications Michael T. Lotze
University of Pittsburgh, United States
2 shared publicationsStefan Duensing
Department of Urology, University of Heidelberg School of Medicine, Heidelberg, Germany
2 shared publicationsWalter J. Storkus
University of Pittsburgh, United States
2 shared publications
Latest Publications
- 28 December 2024
- Published by Wiley in Cytoskeleton
- Vol. 82 (3) , 216-217
Author Profile: Abigail Allen‐Gondringer
- 28 December 2024
- Published by Wiley in Cytoskeleton
- Vol. 82 (3) , 216-217
Author Profile: Abigail Allen‐Gondringer
- Open Access
- 16 September 2023
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 2 (10) , pgad305
Vascular endothelial cell-specific disruption of theprofilin1gene leads to severe multiorgan pathology and inflammation causing mortality
Actin-binding protein Profilin1 is an important regulator of actin cytoskeletal dynamics in cells and critical for embryonic development in higher eukaryotes. The objective of the present study was to examine the consequence of loss-of-function of Pfn1 in vascular endothelial cells (ECs) in vivo. We utilized a mouse model engineered for tamoxifen-inducible biallelic inactivation of the Pfn1 gene selectively in EC (Pfn1EC-KO). Widespread deletion of EC Pfn1 in adult mice leads to severe health complications presenting overt pathologies (endothelial cell death, infarct, and fibrosis) in major organ systems and evidence for inflammatory infiltrates, ultimately compromising the survival of animals within 3 weeks of gene ablation. Mice deficient in endothelial Pfn1 exhibit selective bias toward the proinflammatory myeloid-derived population of immune cells, a finding further supported by systemic elevation of proinflammatory cytokines. We further show that triggering Pfn1 depletion not only directly upregulates proinflammatory cytokine/chemokine gene expression in EC but also potentiates the paracrine effect of EC on proinflammatory gene expression in macrophages. Consistent with these findings, we provide further evidence for increased activation of Interferon Regulatory Factor 7 (IRF7) and STAT1 in EC when depleted of Pfn1. Collectively, these findings for the first time demonstrate a prominent immunological consequence of loss of endothelial Pfn1 and an indispensable role of endothelial Pfn1 in mammalian survival unlike tolerable phenotypes of Pfn1 loss in other differentiated cell types.
- 16 September 2023
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 2 (10) , pgad305
Open AccessVascular endothelial cell-specific disruption of theprofilin1gene leads to severe multiorgan pathology and inflammation causing mortality
Actin-binding protein Profilin1 is an important regulator of actin cytoskeletal dynamics in cells and critical for embryonic development in higher eukaryotes. The objective of the present study was to examine the consequence of loss-of-function of Pfn1 in vascular endothelial cells (ECs) in vivo. We utilized a mouse model engineered for tamoxifen-inducible biallelic inactivation of the Pfn1 gene selectively in EC (Pfn1EC-KO). Widespread deletion of EC Pfn1 in adult mice leads to severe health complications presenting overt pathologies (endothelial cell death, infarct, and fibrosis) in major organ systems and evidence for inflammatory infiltrates, ultimately compromising the survival of animals within 3 weeks of gene ablation. Mice deficient in endothelial Pfn1 exhibit selective bias toward the proinflammatory myeloid-derived population of immune cells, a finding further supported by systemic elevation of proinflammatory cytokines. We further show that triggering Pfn1 depletion not only directly upregulates proinflammatory cytokine/chemokine gene expression in EC but also potentiates the paracrine effect of EC on proinflammatory gene expression in macrophages. Consistent with these findings, we provide further evidence for increased activation of Interferon Regulatory Factor 7 (IRF7) and STAT1 in EC when depleted of Pfn1. Collectively, these findings for the first time demonstrate a prominent immunological consequence of loss of endothelial Pfn1 and an indispensable role of endothelial Pfn1 in mammalian survival unlike tolerable phenotypes of Pfn1 loss in other differentiated cell types.
- Open Access
- 12 July 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (8) , 105044
Vascular endothelial profilin-1 drives a protumorigenic tumor microenvironment and tumor progression in renal cancer
- 12 July 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (8) , 105044
Open AccessVascular endothelial profilin-1 drives a protumorigenic tumor microenvironment and tumor progression in renal cancer
- Open Access
- 1 November 2020
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 295 (46) , 15636-15649
Actin-binding protein profilin1 promotes aggressiveness of clear-cell renal cell carcinoma cells
- 1 November 2020
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 295 (46) , 15636-15649
Open AccessActin-binding protein profilin1 promotes aggressiveness of clear-cell renal cell carcinoma cells
- Open Access
- 1 July 2020
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 295 (28) , 9618-9629
Disruption of profilin1 function suppresses developmental and pathological retinal neovascularization
- 1 July 2020
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 295 (28) , 9618-9629
Open AccessDisruption of profilin1 function suppresses developmental and pathological retinal neovascularization
- 1 May 2019
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 25 (3) , 165-177
Inhibiting Autophagy in Renal Cell Cancer and the Associated Tumor Endothelium
The clear cell subtype of kidney cancer encompasses most renal cell carcinoma cases and is associated with the loss of von Hippel-Lindau gene function or expression. Subsequent loss or mutation of the other allele influences cellular stress responses involving nutrient and hypoxia sensing. Autophagy is an important regulatory process promoting the disposal of unnecessary or degraded cellular components, tightly linked to almost all cellular processes. Organelles and proteins that become damaged or that are no longer needed in the cell are sequestered and digested in autophagosomes upon fusing with lysosomes, or alternatively, released via vesicular exocytosis. Tumor development tends to disrupt the regulation of the balance between this process and apoptosis, permitting prolonged cell survival and increased replication. Completed trials of autophagic inhibitors using hydroxychloroquine in combination with other anticancer agents including rapalogues and high-dose interleukin 2 have now been reported. The complex nature of autophagy and the unique biology of clear cell renal cell carcinoma warrant further understanding to better develop the next generation of relevant anticancer agents.
- 1 May 2019
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 25 (3) , 165-177
Inhibiting Autophagy in Renal Cell Cancer and the Associated Tumor Endothelium
The clear cell subtype of kidney cancer encompasses most renal cell carcinoma cases and is associated with the loss of von Hippel-Lindau gene function or expression. Subsequent loss or mutation of the other allele influences cellular stress responses involving nutrient and hypoxia sensing. Autophagy is an important regulatory process promoting the disposal of unnecessary or degraded cellular components, tightly linked to almost all cellular processes. Organelles and proteins that become damaged or that are no longer needed in the cell are sequestered and digested in autophagosomes upon fusing with lysosomes, or alternatively, released via vesicular exocytosis. Tumor development tends to disrupt the regulation of the balance between this process and apoptosis, permitting prolonged cell survival and increased replication. Completed trials of autophagic inhibitors using hydroxychloroquine in combination with other anticancer agents including rapalogues and high-dose interleukin 2 have now been reported. The complex nature of autophagy and the unique biology of clear cell renal cell carcinoma warrant further understanding to better develop the next generation of relevant anticancer agents.